How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

809 results for

Priapism

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

601. Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

of recurrent leg ulcers; or History of Acute Chest Syndrome within the past five years; or History of priapism requiring medical intervention within the past two years; or History of stroke (but not currently on a chronic blood transfusion regimen). Exclusion Criteria: Use of agents that can induce Hb F within 60 days of Day 1 (i.e. hydroxyurea, butyrates, decitabine, 5-azacytidine, IMiDs, or erythropoietin) Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer Patients who have

2010 Clinical Trials

602. Drug Interaction Study of Avanafil and Enalapril or Amlodipine

, gastrointestinal, pulmonary, endocrine, immunologic, or renal disease, or other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs or place the subjects at increased risk as determined by the Investigator. Any clinically significant laboratory abnormalities as judged by the Investigator. A predisposition to priapism, such as subjects with sickle cell disease or blood dyscrasias. Known history of cardiovascular or cerebrovascular event, or any history of angina

2010 Clinical Trials

603. Hemodynamic Study of Avanafil and Two α-Adrenergic Blockers,Doxazosin and Tamsulosin

to interfere with the absorption, distribution, metabolism, or excretion of drugs or place the subjects at increased risk as determined by the Investigator. Any clinically significant laboratory abnormalities as judged by the Investigator. Inclusion of a subject with out of normal range laboratory values must be approved by VIVUS prior to subject enrollment. A predisposition to priapism, such as subjects with sickle cell disease or blood dyscrasias. Known history of cardiovascular or cerebrovascular event

2010 Clinical Trials

604. Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism

significant chronic haematological disease which may lead to priapism Bleeding disorders Significant active peptic ulceration. Concomitant use of vardenafil with HIV protease inhibitors such as ritonavir and indinavir is contraindicated, as they are potent inhibitors of CYP 3A4 Concomitant use of vardenafil with potent CYP 3A4 inhibitors ketoconazole and itraconazole (oral form) is contra-indicated in men older than 75 years. Patients deemed unable to comply with the requirements of the protocol. Contacts

2010 Clinical Trials

605. Magnesium in Crisis

(avascular necrosis, gall bladder disease, priapism, etc.) patient with greater than 10 admissions for pain crisis in the past year patient maintained on daily opioids or chronic transfusions for chronic sickle cell pain transfusion within the previous two months known kidney or liver failure (elevation of liver function tests does not warrant exclusion) known pulmonary hypertension pregnancy diagnosis of bacterial infection, fever ≥39.5°C, acute chest syndrome, hemodynamic instability or sepsis current

2010 Clinical Trials

606. Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis

) Acute chest syndrome, diagnosed or strongly suspected, as evidenced by a new infiltrate on chest radiograph, and 1 or more of the following: Fever >39° C (102.2° F) Hypoxia (confirmed by arterial blood gases [ABG] with paO2 <70 mmHg) Chest pain Suspicious findings on exam (tachypnea, intercostal retractions, wheezing, and/or rales) Sickle cell disease (SCD) pain atypical of VOC, including hepatic or splenic sequestration, cholecystitis, or pneumonia. Acute stroke, acute priapism, severe avascular

2010 Clinical Trials

607. Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction

Experimental: injection of bone marrow cells Biological: injection of bone marrow mononucleated cells Four different concentration of BMMNC will be tested in four groups of 3 patients. In group 5 (n=19): one cell concentration corresponding to the best dose determined by analysis of the previous groups will be tested. Other Name: cell therapy Outcome Measures Go to Primary Outcome Measures : Absence of serious adverse event (general or local) [ Time Frame: 6 months ] Side effects envisaged: priapism, local

2010 Clinical Trials

608. Sildenafil for Prevention of Cerebral Vasospasm

the third to the 14th day after subarachnoid hemorrhage ] Signs of vasospasm in in transcranial ecodoppler. Mortality [ Time Frame: From the third to the 14th day before subarachnoid hemorrhage. ] General mortality (for any causes). Side effects [ Time Frame: From the third to the 14th day after subarachnoid hemorrhage. ] Drug side effect: hypotension, visual blurring, nasal congestion, angina pectoris, asthma crisis, AV block, digestive bleeding, and priapism. Time to discharge [ Time Frame: From

2010 Clinical Trials

609. Penile abscess and necrotizing fasciitis secondary to neglected false penile fracture (Full text)

Penile abscess and necrotizing fasciitis secondary to neglected false penile fracture Penile infection and abscess formation have been described in association with priapism, cavernosography, intracavernosal injection therapy, trauma and penile prosthesis. We report a case of penile abscess and necrotizing fasciitis of penile skin in a 37-year-old male, presented 3 weeks after neglected false penile fracture.

2010 Urology annals PubMed abstract

610. Supersizing the penis following penile prosthesis implantation. (Abstract)

Supersizing the penis following penile prosthesis implantation. Following implantation of a penile prosthesis, some couples are dissatisfied with penile length, girth, shaft, or glans engorgement. This may be delusional because of the procedure per se or preexisting risk factors such as neglected priapism, Peyronie's disease, radical prostatectomy, or overhanging suprapubic fat.In this work, we try to enhance penile size in patients dissatisfied with its dimensions following implantation

2010 Journal Of Sexual Medicine

611. Leg ulcers in sickle cell disease. (Full text)

recognized since the early times of SCD, there has been little improvement in the efficacy of its management and clinical outcome over the past 100 years. Recently, vasculopathic abnormalities involving abnormal vascular tone and activated, adhesive endothelium have been recognized as another pathway to end organ damage in sickle cell disease. Vasculopathy of sickle cell disease has been implicated in the development of pulmonary hypertension, stroke, leg ulceration and priapism, particularly associated

2010 American journal of hematology PubMed abstract

612. Attenuated RhoA/Rho-kinase Signaling in Penis of Transgenic Sickle Cell Mice. (Full text)

Attenuated RhoA/Rho-kinase Signaling in Penis of Transgenic Sickle Cell Mice. The Ras homolog gene family, member A (RhoA) and its main downstream effector, Rho-kinase (ROCK) are important in maintaining the penis in the flaccid state. The pathophysiology of sickle cell disease-associated priapism is not well defined. We hypothesized that the RhoA/ROCK vasoconstrictive pathways might be involved in the development of priapism. Therefore, the objective of the present study was to evaluate (...) . No change in ROCK1 protein expression was observed in either cohort of mice penises.These data suggest that sickle cell disease associated-priapism might be contributed by a lack of RhoA/ROCK-mediated vasoconstriction and highlight a novel molecular mechanism in the pathophysiology of priapism.Copyright 2010 Elsevier Inc. All rights reserved.

2010 Urology PubMed abstract

613. A Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Study in Men With Premature Ejaculation

, within last 6 months. History of prostate cancer treated or untreated. History of prostatectomy or prostate procedures for any cause. Clinically significant chronic hematological disease which may lead to priapism such as sickle cell anemia, multiple myeloma or leukemia. Significant active peptic ulceration. Presence of the following conditions prior to screening: myocardial infarction, coronary bypass surgery, coronary artery angioplasty, unstable angina, clinically evident congestive heart failure

2009 Clinical Trials

614. Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Avanafil

to be developed into priapism such as sickle cell disease, multiple myeloma, leukemia subjects who have retinitis pigmentosa subjects who suffered from serious GI bleeding disorder within 1 year subjects who took other PDE5 inhibitors or ED therapies within 2 weeks subjects who use non-concomitant medications(Nitrate/NO donors, Androgens, anti-androgen, trazodone, Anticoagulant,over-the-counter drugs known to inhibit the activity of CYP3A4) history of hypersensitivity to the PDE5 inhibitors or not responded

2009 Clinical Trials

615. Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease

Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Diagnosis of sickle cell disease Clinically significant disease defined as at least 1 painful episode per year averaged over the previous 3 years or a history of priapism, stroke, acute chest syndrome, avascular necrosis, multi-organ failure or the need for chronic narcotic medications for pain from sickle cell disease Must have failed a previous attempt at treatment with hydroxyurea defined

2009 Clinical Trials

616. Efficacy Study of RX-10100 to Treat Major Depressive Disorder (MDD)

Criteria: Have a BMI > 40 or < 18 Unstable angina pectoris History of myocardial infarction, stroke, or life-threatening arrhythmia within the prior 6 months Uncontrolled atrial fibrillation/flutter at screening Severe chronic or acute liver disease; history of moderate or severe hepatic impairment Clinically significant chronic hematological disease which may lead to priapism, such as sickle cell anemia and leukemia Bleeding disorder Resting hypotension or hypertension History of malignancy (cancers

2009 Clinical Trials

617. Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease

: No Criteria Inclusion Criteria: Diagnosis of SCD or sickle beta thalassemia (excluding Hemoglobin C) Between 12 and 60 years of age, inclusive At least one episode of a SCD-related crisis or complication (e.g., vaso-occlusive crisis, acute chest syndrome, priapism) per year for an average of 3 years or one episode of acute chest syndrome over the prior 5 years Screening (untransfused) HbF level >/= 2% as analyzed by a central laboratory If receiving hydroxyurea therapy, must be receiving a stable dose

2009 Clinical Trials

618. Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs

-identical, but unrelated, donor or 1 human leukocyte antigen (HLA) allele mismatched bone marrow or up to 2 HLA antigen mismatched umbilical cord blood (UCB) donor with one or more of the following: Stroke, central nervous system (CNS) hemorrhage or a neurologic event lasting longer than 24 hours. Acute chest syndrome with a history of recurrent hospitalizations or exchange transfusions. Recurrent vaso-occlusive pain, 3 or more episodes per year for 3 years or more years; or recurrent priapism. Impaired

2009 Clinical Trials

619. Nitric Oxide Therapy for Acute Chest Syndrome in Sickle Cell Disease Children

intubation with mechanical ventilation Isolated acute asthmatic crisis stroke or priapism with emergency acute transfusion needed acute anemia with hemoglobin drop of more than 20% as compared to steady state hemoglobin chronic long term transfusion therapy nitric oxyde hypersensitivity patients with right-left extra-pulmonary cardiac shunt patient previously included in the protocol patient participating in another interventional protocol pregnancy or breast feeding Contacts and Locations Go

2009 Clinical Trials

620. Risperidone-Induced Priapism: A Case Report (Full text)

Risperidone-Induced Priapism: A Case Report 19750074 2011 07 14 2018 11 13 1523-5998 11 4 2009 Primary care companion to the Journal of clinical psychiatry Prim Care Companion J Clin Psychiatry Risperidone-induced priapism: a case report. 174-5 10.4088/PCC.08l00666 Sharma Ashish A Department of Psychiatry, University of Nebraska Medical Center, Omaha. Fleisher Mark H MH eng Journal Article United States Prim Care Companion J Clin Psychiatry 100887410 1523-5998 2009 9 15 6 0 2009 9 15 6 0 2009 9

2009 Primary Care Companion to the Journal of Clinical Psychiatry PubMed abstract

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>